SEC Comment Letter 0000000000-23-008614 to NextCure, Inc. (NXTC)
NextCure, Inc.
Date: Aug. 8, 2023 · CIK: 0001661059 · Accession: 0000000000-23-008614
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273723
Letter
United States securities and exchange commission logo August 8, 2023 Michael Richman Chief Executive Officer NextCure, Inc. 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 Re:NextCure, Inc. Registration Statement on Form S-3 Filed August 4, 2023 File No. 333-273723 Dear Michael Richman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kostian Ciko
Show Raw Text
United States securities and exchange commission logo
August 8, 2023
Michael Richman
Chief Executive Officer
NextCure, Inc.
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
Re:NextCure, Inc.
Registration Statement on Form S-3
Filed August 4, 2023
File No. 333-273723
Dear Michael Richman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Kostian Ciko